- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 435KB)
Carfilzomib – March 2022
Carfilzomib: Powder for injection 10 mg, Powder for injection 30 mg, Powder for injection 60 mg; Kyprolis®
Last updated
1 July 2022